Copyright
©2014 Baishideng Publishing Group Inc.
World J Gastrointest Pathophysiol. Nov 15, 2014; 5(4): 392-399
Published online Nov 15, 2014. doi: 10.4291/wjgp.v5.i4.392
Published online Nov 15, 2014. doi: 10.4291/wjgp.v5.i4.392
Table 2 Current regimens to treat Helicobacter pylori infection
| Treatment | Regimen |
| Bismuth-containing quadruple therapy | A PPI (standard dose, bid), bismuth (standard dose, qid) tetracycline (500 mg, qid) and metronidazole (500 mg, qid) for 10-14 d |
| Sequential therapy | A 5-d dual therapy with a PPI (standard dose, bid) and amoxicillin (1 g, bid) followed by a 5-d triple therapy with a PPI (standard dose, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid) |
| Concomitant therapy | A PPI (standard dose, bid), clarithromycin (500 mg, bid), amoxicillin (1 g, bid) and metronidazole (500 mg, bid) for 7-10 d |
| Hybrid therapy | A 7-d dual therapy with a PPI (standard dose, bid) and amoxicillin (1 g, bid) followed by a 7-d quadruple therapy with a PPI (standard dose, bid), amoxicillin (1 g, bid), clarithromycin (500 mg, bid) and metronidazole (500 mg, bid) |
| Levofloxacin-based triple therapy | A PPI (standard dose, bid), levofloxacin (500 mg, bid) and amoxicillin (1 g, bid) for 10 d |
-
Citation: Papastergiou V, Georgopoulos SD, Karatapanis S. Treatment of
Helicobacter pylori infection: Past, present and future. World J Gastrointest Pathophysiol 2014; 5(4): 392-399 - URL: https://www.wjgnet.com/2150-5330/full/v5/i4/392.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v5.i4.392